2-(二氟甲氧基)苯胺 | 22236-04-0

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 2-(二氟甲氧基)苯胺
• 中文别名: 2-二氟甲氧基苯胺；邻二氟甲氧基苯胺；邻(二氟甲氧基)苯胺
• 英文名称: 2-(difluoromethoxy)aniline
• CAS: 22236-04-0
• 化学式: C₇H₇F₂NO
• mdl: MFCD00190104
• 分子量: 159.135
• InChiKey: CGNAIUUCOVWLLL-UHFFFAOYSA-N

物化性质

• 沸点：
  205 °C(lit.)
• 密度：
  1.272 g/mL at 25 °C(lit.)
• 闪点：
  199 °F
• 稳定性/保质期：
  如果遵照规格使用和储存，则不会分解，请避免接触氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn,T
• 安全说明：
  S36
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2922299090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险标志：
  GHS07
• 危险品运输编号：
  2811
• 危险性描述：
  H302,H312,H332
• 危险性防范说明：
  P280
• 储存条件：
  保持贮藏器密封，并将其放入一个紧密的容器中。储存在阴凉、干燥的地方。

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : 2-(Difluoromethoxy)aniline
CAS-No. : 22236-04-0
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Inhalation (Category 4)
Acute toxicity, Dermal (Category 4)
Acute toxicity, Oral (Category 4)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful by inhalation, in contact with skin and if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
H312 Harmful in contact with skin.
H332 Harmful if inhaled.
Precautionary statement(s)
P280 Wear protective gloves/ protective clothing.
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R20/21/22 Harmful by inhalation, in contact with skin and if swallowed.
S-phrase(s)
S36 Wear suitable protective clothing.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Formula : C7H7F2NO
Molecular Weight : 159,13 g/mol
Component Concentration
2-(Difluoromethoxy)aniline
CAS-No. 22236-04-0 -

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with
water. Consult a physician.
Most important symptoms and effects, both acute and delayed
Absorption into the body leads to the formation of methemoglobin which in sufficient concentration causes
cyanosis. Onset may be delayed 2 to 4 hours or longer., To the best of our knowledge, the chemical,
physical, and toxicological properties have not been thoroughly investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
For small (incipient) fires, use media such as "alcohol" foam, dry chemical, or carbon dioxide. For large
fires, apply water from as far as possible. Use very large quantities (flooding) of water applied as a mist or
spray; solid streams of water may be ineffective. Cool all affected containers with flooding quantities of
water.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen fluoride
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
Use water spray to cool unopened containers.

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation.
Remove all sources of ignition. Beware of vapours accumulating to form explosive concentrations.
Vapours can accumulate in low areas.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and
place in container for disposal according to local regulations (see section 13). Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid inhalation of vapour or mist.
Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic
charge.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator
with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup
to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air
respirator. Use respirators and components tested and approved under appropriate government
standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: liquid
Colour: brown
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 205 °C - lit.
boiling range
g) Flash point 93 °C - closed cup
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,272 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
Heat, flames and sparks.
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation Harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin Harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Signs and Symptoms of Exposure
Absorption into the body leads to the formation of methemoglobin which in sufficient concentration causes
cyanosis. Onset may be delayed 2 to 4 hours or longer., To the best of our knowledge, the chemical,
physical, and toxicological properties have not been thoroughly investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
This combustible material may be burned in a chemical incinerator equipped with an afterburner and
scrubber. Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed
professional waste disposal service to dispose of this material.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine Pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

制备方法与用途

2-(二氟甲氧基)苯胺可作为有机合成中间体和医药中间体，主要用于实验室研发过程和化工医药生成过程中。

制备方法如下：将铁粉（5当量）加入到2-(二氟甲氧基)硝基苯（1当量）溶解于MeOH/MeCOOH（1:1）的溶液中。在氮气保护下，于50°C加热反应混合物3小时。随后，真空浓缩反应混合物。将剩余固体残余物加入到EtOAc (100mL) 和 1M NaOH (50mL) 中。通过离心分离沉淀，并分开水层和有机层。用水相用 EtOAc (3 × 50 mL) 萃取三次，合并所有有机层和萃取物，使用 MgSO4 干燥，然后过滤混合的有机层和萃取液。最后，真空浓缩得到目标产物。

反应信息

• 作为反应物：
  描述：

  2-(二氟甲氧基)苯胺 在 盐酸 、 sodium nitrite 、 二氧化硫 、 copper dichloride 作用下， 以 水 、 溶剂黄146 、 乙腈 为溶剂， 反应 8.17h， 以55%的产率得到2-(二氟甲氧基)苯磺酰氯
  参考文献：
  名称：

  [EN] COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS
  [FR] COMPOSÉS PERMETTANT DE RÉGULER LES VOIES FAK ET/OU SRC

  摘要：

  本申请提供了新颖的可选择替代的融合吡啶和嘧啶双环化合物及其药用可接受盐。还提供了制备这些化合物的方法。通过向受试者投予一种或多种化合物的治疗有效量，这些化合物在共调节FAK和/或Src活性方面具有用处。通过这样做，这些化合物在治疗与FAK和/或Src途径失调相关的疾病方面具有有效性。这些化合物作为双重FAK和/或Src抑制剂表现出优势。可以使用这些化合物治疗各种疾病，包括以炎症或异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  WO2015038417A1
• 作为产物：
  描述：

  2-(二氟甲氧基)硝基苯 在 palladium on activated charcoal 氢气 作用下， 以 乙醇 、 水 为溶剂， 反应 0.33h， 以76%的产率得到2-(二氟甲氧基)苯胺
  参考文献：
  名称：

  1-（二氟甲氧基苯基）喹诺酮-3-羧酸的合成及体外抗菌活性

  摘要：

  我们报道了其中二氟甲氧基部分被用作卤素替代物的N-1-苯基喹诺酮的合成。关于N-1-卤代苯基喹诺酮类药物的抗菌活性进行了讨论。

  DOI：

  10.1002/jps.2600780716

文献信息

• 吡唑并[3,4-c]吡啶类衍生物
  申请人：石药集团中奇制药技术(石家庄)有限公司

  公开号：CN105384739B

  公开（公告）日：2020-03-20

  吡唑并[3,4‑c]吡啶类衍生物。本发明涉及下式（I）的化合物，其互变异构体、其光学异构体、或其药学上可接受的盐：Z，X，RNc，RNd，RNe和RNf如权利要求1所定义。本发明还涉及包含上述化合物的药物组合物。本发明还涉及上述化合物或药用组合物在制备用于预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途，特别是在制备用于在低出血风险的情况下预防和/或治疗抑制Xa因子正性影响疾病的药物中的用途。
• [EN] ARYLAMINE SUBSTUTUTED BICYCLIC HETEROAROMATIC COMPOUNDS AS P38 KINASE INHIBITORS<br/>[FR] COMPOSES BICYCLIQUES HETEROAROMATIQUES ARYLAMINE SUBSTITUEE UTILISES EN TANT QU'INHIBITEURS DE KINASE P38
  申请人：CELLTECH R&D LTD

  公开号：WO2004000846A1

  公开（公告）日：2003-12-31

  Bicyclic heteroaromatic derivatives of formula (1) are described: F (1) where: the dashed line joining A and C(Ra) is present and represents a bond and A is a -N= atom or a -C(Rb)= group, or the dashed line is absent and A is a -N(Rb)-, or -C(Rb)(Rc)- group; X is an -O-, -S- or substituted nitrogen atom or a -S(O)-, -S(O2)- or -NH­-group; Y is a nitrogen or substituted carbon atom or a -CH= group; n is zero or the integer 1; Alk1 is an optionally substituted aliphatic or heteroaliphatic chain L1 is a covalent bond or a linker atom or group; Cy1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the remaining substituents are defined in the specification. The compounds are potent and selective inhibitors of p38 kinase and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

  公式（1）描述了具有双环杂芳衍生物：F（1）其中：连接A和C（Ra）的虚线存在且表示键，A是一个-N=原子或一个-C（Rb）=基团，或者虚线不存在且A是一个-N（Rb）-或-C（Rb）（Rc）-基团；X是一个-O-，-S-或取代的氮原子或一个-S（O）-，-S（O2）-或-NH­-基团；Y是一个氮或取代的碳原子或一个-CH=基团；n为零或整数1；Alk1是一个可选择取代的脂肪或杂原脂肪链L1是一个共价键或连接原子或基团；Cy1是一个氢原子或一个可选择取代的环脂肪，多环脂肪，杂环脂肪，多杂环脂肪，芳香或杂芳基团；Ar是一个可选择取代的芳香或杂芳基团；其余取代基在规范中定义。这些化合物是p38激酶的有效和选择性抑制剂，并可用于预防和治疗免疫或炎症性疾病。
• [EN] ANTI-AMYLOID COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ANTI-AMYLOÏDES ET PROCÉDÉS
  申请人：TREVENTIS CORP

  公开号：WO2012119035A1

  公开（公告）日：2012-09-07

  Anti-amyloid compounds are provided along with methods of use thereof.

  反淀粉样蛋白化合物及其用途方法。
• [EN] COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES<br/>[FR] COMPOSÉS ET PROCÉDÉS PERMETTANT DE TRAITER DES MALADIES DÉPENDANT DE MÉTALLOPROTÉASES À ZINC MATRICIELLES
  申请人：ABSOLUTE SCIENCE INC

  公开号：WO2009045761A1

  公开（公告）日：2009-04-09

  The present invention provides compounds and methods for treating zinc matrix metalloprotease dependent diseases. In certain embodiments, the compounds of the present invention have the following formulas:

  本发明提供了用于治疗锌基质金属蛋白酶依赖性疾病的化合物和方法。在某些实施例中，本发明的化合物具有以下公式：
• [EN] NOVEL ULK1 INHIBITORS AND METHODS USING SAME<br/>[FR] NOUVEAUX INHIBITEURS D'ULK 1 ET LEURS MÉTHODES D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2016033100A1

  公开（公告）日：2016-03-03

  In certain aspects, the invention provides a method for treating a disease or condition in a subject, the method comprising co-administering to a subject in need thereof a therapeutically effective amount of at least one ULK1-inhibiting pyrimidine, and a therapeutically effective amount of an mTOR inhibitor.

  在某些方面，该发明提供了一种治疗受试者疾病或病况的方法，该方法包括向需要的受试者联合给予至少一种ULK1抑制嘧啶的治疗有效量，以及mTOR抑制剂的治疗有效量。